Spineway Reports Revenue of €12.4 Million in 2025
Spineway, a specialist in spinal implants, achieved an annual revenue of €12.4 million in 2025, up by 4%, according to the press release published on January 13. The group saw a significant acceleration in sales in the fourth quarter, driven by all its geographical areas.
Strong Fourth Quarter Performance
The last quarter of 2025 generated revenue of €3.8 million, a 34% increase compared to the same period in 2024, the company reports. This performance is attributed by the group to an acceleration of sales across all its areas of operation and to the postponement of orders initially expected in the first half of the year. The data presented remains consolidated and unaudited at this stage. Over the entire year, the company closed with a 4% growth in activity, despite several operational constraints encountered during the year. Spineway specifically mentions delays in certifications in Latin America, delays in the awarding of tenders in Asia, and supply tensions with some subcontractors.
Benefits of Geographical Diversification Strategy
The group highlights the benefits of its geographical diversification strategy to explain this annual performance. According to the press release, Spineway has opened new territories, particularly in Asia and Latin America, which has allowed it to offset difficulties encountered in certain markets. The company has a global network of more than 50 independent distributors and generates more than 75% of its revenue from exports. For 2026, the group plans to obtain new certifications for its premium ranges, Distimp and Spine Innovations, in the Latin America and Asia zones, in line with its commercial development strategy. These certifications are expected to enable the group to expand its offering in these promising markets.
Focused on Severe Spinal Pathologies
Spineway designs, manufactures, and markets a range of implants and surgical instruments aimed at treating severe spinal pathologies. With its strong commercial dynamics and diversified geographical presence, the group believes it has the necessary assets to sustainably consolidate its positions, according to the press release. The company aims to become a major player in spine surgery. The group will publish its annual results for 2025 on February 17, 2026. Spineway is listed on Euronext Growth Paris and eligible for the PEA-PME scheme.
